Company profileMixed portfolio#643 of 1,318 in Pakistan✓ No DRAP alerts

KOBEC

Mixed portfolio · 20 pharmaceutical brands of 16 registrations

Ranked #6 of 23 companies in Eye Conditions

16 registered products 20 pharmaceutical brands 18 distinct molecules 0 DRAP alerts
Part of this company's portfolio (“Eye”) is registered under a broad DRAP category rather than distinct molecules, so the molecule count understates its true range.

Company overview

16
registered products
20
pharmaceutical brands
18
distinct molecules
5
therapeutic classes
0
DRAP alerts

KOBEC is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 16 product registrations across 18 distinct molecules. Its portfolio is concentrated in Eye Conditions and Anti-Infective, Ophthalmologicals. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by KOBEC

15 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Anti-Infective, Ophthalmologicals 1

Top molecules by brand count

Therapeutic classes

Eye Conditions · 10Anti-Infective, Ophthalmologicals · 3Other Ophthalmologicals, Lubricant · 2Antiinflammatory Agents And Antiinfectives In Combination · 1Mydriatics And Cycloplegics · 1

Conditions treated

Allergy/Infections · 5Dry Eye/Allergy · 3PAIN · 1Glaucoma/Mydriasis · 1

Price band (DRAP official ceilings)

Registered products priced by source
DVAGO8 products · Rs 145.48 – Rs 902.5
Servaid10 products · Rs 68.6 – Rs 742.43
Median across source: Rs 339.56

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Barrett Hodgson Pakistan (Private) Ltd. holds 165 molecules not in this portfolio
Acetylsalicylic AcidAmlodipineArtemetherAspirinAtorvastatinAzithromycin
Sante (Private) Limited holds 72 molecules not in this portfolio
AcyclovirAmlodipineArtemetherAzithromycinAzithromycin Azithromycin DihydarteBenzoyl Peroxide
VEGA PHARMACEUTICALS LTD. holds 2 molecules not in this portfolio
NepafenacOlopatadine

Get the full profile for KOBEC

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.